# Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis

> **NCT00185510** · PHASE4 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 250 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** Methylprednisolone Aceponate (Advantan, BAY86-4862)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00185510
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2006-05
- **Final completion:** 2006-06
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2023-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185510, "Efficacy and Safety Study of Advantan for Maintenance Treatment of Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00185510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*